Condition: Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia · Sponsor: Crinetics Pharmaceuticals Inc.
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
This description comes directly from the study's public registry record.
Crinetics Clinical Trials · 833-827-9741 · clinicaltrials@crinetics.com
Always discuss trial participation with your own doctor first.
| Crinetics Study Site | Los Angeles, California, United States | Recruiting |
| Crinetics Study Site | Atlanta, Georgia, United States | Recruiting |
| Crinetics Study Site | Chicago, Illinois, United States | Recruiting |
| Crinetics Study Site | Baltimore, Maryland, United States | Recruiting |
| Crinetics Study Site | Ann Arbor, Michigan, United States | Recruiting |
| Crinetics Study Site | Minneapolis, Minnesota, United States | Recruiting |
| Crinetics Study Site | Rochester, Minnesota, United States | Recruiting |
| Crinetics Study Site | Pittsburgh, Pennsylvania, United States | Recruiting |
| Crinetics Study Site | Dallas, Texas, United States | Recruiting |
| Crinetics Study Site | Milwaukee, Wisconsin, United States | Recruiting |
| Crinetics Study Site | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
| Crinetics Study Site | Buenos Aires, Buenos Aires F.D., Argentina | Recruiting |
+ 43 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07144163